Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma
NCT03005418 · View on ClinicalTrials.gov ↗
Study Summary
This study evaluates the use of the Human Acellular Vessel (HAV) in adults with vascular trauma below the neck who are undergoing vascular reconstructive surgery. There will be a torso cohort and a limb cohort. All subjects will be implanted with a HAV as an interposition vessel or bypass using standard vascular surgical techniques. There is no control arm.
Conditions Studied
Interventions
- BIOLOGICAL Human Acellular Vessel (HAV)
Study Locations (20)
California
- Jacob Medical Center at UC San Diego — La Jolla
- Keck Hospital of University of Southern California (USC) — Los Angeles
- Cedars-Sinai Medical Cener — Los Angeles
- UCI Medical Center — Orange
- University California, Davis — Sacramento
- University of California San Diego (UCSD) Medical Center — San Diego
Florida
- UF Health Jacksonville — Jacksonville
- Jackson South Medical Center — Miami
- Ryder Trauma Center — Miami
- Tampa General Hospital — Tampa
Maryland
- R Adams Cowley Baltimore Shock Trauma — Baltimore
- Johns Hopkins Bayview Medical Center — Baltimore
- Johns Hopkins Hospital — Baltimore
New Jersey
- Cooper University Hospital — Camden
- Rutgers New Jersey Medical School — Newark
Colorado
- Ernest E Moore Shock Trauma Center at Denver Health — Denver
Georgia
- Grady Memorial Hospital — Atlanta
Minnesota
- Mayo Clinic — Rochester
Missouri
- Saint Louis University (SLU) — St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03005418
The ClinicalTrials.gov registry entry for NCT03005418 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Humacyte, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Trauma appearing as the primary indexed condition, and to 1 intervention — of which Human Acellular Vessel (HAV) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03005418 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Florida, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03005418 about?
NCT03005418 is a clinical study titled "Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma". This study evaluates the use of the Human Acellular Vessel (HAV) in adults with vascular trauma below the neck who are undergoing vascular reconstructive surgery. There will be a torso cohort and a limb cohort. All subjects will be implanted with a HAV as an interposition vessel or bypass using stan...
What is the current status of trial NCT03005418?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2018-09-01. Estimated completion is 2027-09-01.
What conditions does trial NCT03005418 study?
This clinical trial studies the following conditions: Trauma, Vascular System Injury. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03005418?
The interventions under investigation include: Human Acellular Vessel (HAV) (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03005418?
This trial is sponsored by Humacyte, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03005418 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.